The EPS beat and margin expansion are positive, but the full-year guidance was unchanged from the prior quarter, suggesting no acceleration in the second half. Watch for the Q4 2026 report to see if currency-neutral revenue growth can sustain or improve from the 0.7% level.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $369.00entry
- T+1 · 11d ago +3.41%α +3.09% · $381.57
- T+5 · 5d ago +0.40%α −2.89% · $370.48
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bio-Rad reported Q3 2026 non-GAAP EPS of $2.65, beating the $2.23 consensus by 18.8%, and revenue of $656.4M, slightly above the $650.0M estimate. Non-GAAP operating margin expanded 100bps YoY to 12.8%, and the company maintained its full-year 2026 guidance for currency-neutral revenue decline of 3.0% to growth of 0.5% and non-GAAP operating margin of 10.0-12.0%. GAAP results included a $49.8M impairment charge and $77.2M in restructuring costs, driving a GAAP operating loss.
Key Financial Metrics
Key Facts
- Q3 2026 non-GAAP EPS $2.65 vs consensus $2.23 (beat by 18.8%)
- Q3 2026 revenue $656.4M vs consensus $650.0M (beat by 1.0%)
- Reported revenue +0.5% YoY; currency-neutral revenue +0.7% YoY
- Non-GAAP gross margin 54.5% (+100bps YoY); non-GAAP operating margin 12.8% (+100bps YoY)
- GAAP operating loss of $49.7M due to $77.2M restructuring costs and $49.8M impairment of purchased intangibles
- Full-year 2026 guidance maintained: currency-neutral revenue decline of 3.0% to growth of 0.5%; non-GAAP operating margin 10.0-12.0%
- Clinical Diagnostics segment revenue +2.8% currency-neutral; Life Science segment revenue -2.4% currency-neutral
- Free cash flow $65.2M in Q3 2026 vs $89.2M in Q3 2025
- Net cash from operations $96.4M in Q3 2026 vs $120.9M in Q3 2025
Financial Impact
Non-GAAP EPS beat consensus by $0.42 (18.8%); revenue beat by $6.4M (1.0%); non-GAAP operating margin expanded 100bps YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Life Science | $254.6M | -2.8% |
| Clinical Diagnostics | $401.8M | +2.7% |
Risk Factors
- Life Science segment continues to decline (-2.4% currency-neutral) due to weak academic research market and lower process chromatography sales
- GAAP results show significant restructuring ($77.2M) and impairment ($49.8M) charges
- Free cash flow declined 27% YoY to $65.2M
- Full-year guidance unchanged and still includes potential revenue decline of up to 3.0%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000012208-26-000057 |
| Document: bio-20261104.htm | 0000012208-26-000057 |
| Document: a3q26earningspresentatio.htm | 0000012208-26-000057 |
| Document: 0000012208-26-000057-index-headers.html | 0000012208-26-000057 |
| Document: 0000012208-26-000057-index.html | 0000012208-26-000057 |
| Document: 0000012208-26-000057.txt | 0000012208-26-000057 |
| 8-K Data (Synthetic) | 0000012208-26-000057 |
Track record
9 reports on BIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $370.48 Now $360.26 −2.76% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $386.00 Now $360.26 −6.67% settles Nov 18
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $388.31 to $360.26 Now $360.26 +7.22% ▲ +7.22% +5.53% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $369.00 to $370.48 Now $360.26 −2.37% ▲ +0.40% −2.89% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $385.12 to $379.99 Now $360.26 −6.46% ▼ −1.33% −0.62% vs SPY
- Sep 10, 20269w ago Court Ruling Bearish 5/10 Entry $369.32 to $376.41 Now $360.26 +2.45% ▼ −1.92% −2.26% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $285.94 to $282.44 Now $360.26 +25.99% ▼ −1.22% −1.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers